



## MSF AT THE 48<sup>TH</sup> UNION WORLD CONFERENCE ON LUNG HEALTH Guadalajara, Mexico | 11 – 14 October 2017

### MSF EVENTS

**endTB Symposium: Accelerating TB elimination through access to bedaquiline and delamanid** **October 12**  
*Hall 10 - Jalisco Hall* 14:00 – 15:30

The symposium will provide an update on the UNITAID-funded endTB initiative and findings, including culture conversion and reversion and adverse events for the 600 people who have received bedaquiline or delamanid.

**Community space (Encuentro) session: Five urgent improvements to DR-TB treatment** **October 13**  
*Foro - Encuentro Expo* 17:00 – 18:00

Evidence for treatment with newer DR-TB drugs, shorter treatment regimens, ambulatory care instead of hospitalisation, and fast-track registration of new drugs.

**MSF Symposium: Reducing catastrophic costs for people with TB through patient-centred care** **October 14**  
*Hall 10 - Jalisco Hall* 10:30 – 12:00

Session will analyse the barriers to reducing costs and burden for people with drug-resistant TB including: decentralised and ambulatory treatment, shorter treatment and newer drugs to reduce toxicity, and interventions to reduce out-of-pocket costs of treatment.

### ORAL ABSTRACTS

#### **TB POLICIES**

**Many national TB programmes are out of step with international recommendations for testing, treatment and prevention: results of a 30 country survey** **October 12**  
*Hall 2 – Events Ballroom* 16:00 – 17:30  
SOA-365-12

**Setting up an active pharmacovigilance system for the endTB project** **October 13**  
*Hall 13 - Jalisco Hall* 10:30 – 12:00  
OA-160-13

#### **DRUG-RESISTANT TB TREATMENT**

**Early safety and efficacy of bedaquiline and delamanid combination for drug-resistant TB in Armenia, India and South Africa** **October 13**  
*Plenary Hall* 10:30-12:00  
OA-2905-13

**Adverse events over 6 months with delamanid in a programmatic setting in Khayelitsha, South Africa** **October 13**  
*Hall 13 – Jalisco Hall* 10:30 – 12:00  
OA-162-13

**Safety of multidrug resistant tuberculosis treatment amongst patients receiving bedaquiline in a compassionate use program in Armenia and Georgia** **October 13**  
*Hall 13 – Jalisco Hall* 10:30 – 12:00  
OA-163-13

**Risk factors for developing hypothyroidism among MDR-TB patients receiving Eto and/or PAS in Maputo, Mozambique** **October 13**  
*Hall 13 – Jalisco Hall* 10:30 – 12:00  
OA-164-13

<b>Psychiatric comorbidity among drug-resistant tuberculosis patients</b> <i>Hall 13 – Jalisco Hall</i>	<b>October 13</b> 10:30 – 12:00 OA-167-13
<b>Culture conversion and reversion of multidrug resistant tuberculosis patients receiving bedaquiline in a compassionate use program in Armenia and Georgia</b> <i>Hall 13 – Jalisco Hall</i>	<b>October 13</b> 16:00 – 17:30 OA-188-13
<b>Bedaquiline- and linezolid-based regimens for fluoroquinolone-resistant MDR-TB: how much better is it?</b> <i>Hall 13 – Jalisco Hall</i>	<b>October 13</b> 16:00 – 17:30 OA-190-13
<b>Outcomes of multidrug resistant tuberculosis patients receiving Bedaquiline in a compassionate use program in Armenia and Georgia</b> <i>Hall 13 – Jalisco Hall</i>	<b>October 13</b> 16:00 – 17:30 OA-192-13
<b>Delamanid for rifampicin-resistant tuberculosis: an observational cohort study from Khayelitsha, South Africa</b> <i>Hall 13 – Jalisco Hall</i>	<b>October 13</b> 16:00 – 17:30 OA-193-13

#### **TB DIAGNOSTICS**

<b>Value of determine-TB LAM test as screening test and as diagnostic tool for tuberculosis diagnosis in HIV positive adults</b> <i>Hall 8 – Events Ballroom</i>	<b>October 13</b> 10:30 – 12:00 SOA-402-13
<b>Cost-effectiveness of including determine TB-LAM test to diagnose tuberculosis in HIV-positive symptomatic patients</b> <i>Hall 4 – Events Ballroom</i>	<b>October 14</b> 10:30 – 12:00 SOA-443-14

#### **LATENT TB INFECTION**

<b>Incidence of latent tuberculosis infection and tuberculosis disease after 24 months follow-up in paediatric contacts of drug-resistant tuberculosis patients in Armenia</b> <i>Hall 13 - Jalisco Hall</i>	<b>October 12</b> 14:00 – 15:30 SOA-360-12
---	--

#### **CO-INFECTIONS (HCV)**

<b>High rates of active hepatitis C amongst multidrug resistant tuberculosis patients in Armenia</b> <i>Hall 14 - Jalisco Hall</i>	<b>October 12</b> 10:30 – 12:00 OA-125-12
---	---

### **POSTER PRESENTATIONS**

*All poster presentations take place in the Poster Area from 12:45 – 13:45 on the designated date*

#### **TB POLICIES**

<b>Threats to affordable quality second-line TB drugs in Eastern Europe/Central Asia as the Global Fund shifts to national procurement</b>	<b>October 14</b> PD-893-14
--	--------------------------------

#### **DRUG-RESISTANT TB TREATMENT**

<b>Introduction of a short standardized course of treatment for multidrug-resistant Tuberculosis in Mozambique: cohort description and early culture conversion in HIV-positive and HIV-negative patients</b>	<b>October 12</b> PD-537-12
<b>Outcomes and risk factors in a program treating MDR-TB in Swaziland for 2011-2013 cohorts</b>	<b>October 12</b> PD-547-12
<b>Drug induced hypothyroidism during treatment for multidrug resistant tuberculosis in Swaziland</b>	<b>October 13</b>

	PD-685-13
<b>Lessons learned from the design, development, and deployment of endTB electronic medical record for MDR-TB across 16 countries</b>	<b>October 13</b> PD-700-13
<b>Interim report on the use of a short, simplified regimen for the treatment of children with multidrug-resistant tuberculosis in Karakalpakstan, Uzbekistan</b>	<b>October 13</b> PD-809-13
<b>Accelerating access to delamanid for rifampicin-resistant tuberculosis in Khayelitssha, South Africa</b>	<b>October 14</b> PD-891-14
<b>The impact of pyrazinamide resistance upon the treatment outcome of patients with multidrug-resistant tuberculosis in Karakalpakstan, Uzbekistan</b>	<b>October 14</b> PD-894-14
<b>TB DIAGNOSTICS</b>	
<b>Evaluation of the OMNIgene® SPUTUM reagent for long term transportation of samples for Xpert testing in a high TB-HIV setting</b>	<b>October 13</b> PD-837-13
<b>Does the determine-TB LAM test have a potential value in tuberculosis diagnosis among severely acute malnourished (SAM) children?</b>	<b>October 14</b> PD-924-14
<b>LATENT TB INFECTION</b>	
<b>Discordances between TST and IGRA to detect latent tuberculosis infection in paediatric contacts of drug-resistant tuberculosis patients</b>	<b>October 14</b> PD-944-14

## **REPORTS**

For MSF TB reports, including OUT OF STEP go to: <https://www.msfacecess.org/tb>